HT-29 MTX E12 Cells

HT-29-MTX-E12 is a goblet cell-like subclone derived from the human colorectal adenocarcinoma cell line HT29 through selection with methotrexate (MTX), a process that induces differentiation toward mucus-secreting phenotypes. Among several subclones developed from HT29-MTX, the E12 subclone stands out due to its robust formation of confluent monolayers with tight junctions and a significantly thick, continuous mucus layer on the apical surface. This subclone features a higher proportion of mature goblet cells, as demonstrated by Alcian Blue staining, transmission electron microscopy (TEM), and expression of mucin genes MUC1 and MUC2. In fact, MUC1 and MUC2 mRNA levels were substantially higher in HT-29-MTX-E12 compared to other subclones and parent HT29 cells, correlating with a mucus thickness of approximately 142 ± 51 µm-comparable to the in vivo intestinal environment.

Functionally, HT-29-MTX-E12 has been shown to model the barrier properties of the human intestinal mucus layer, particularly in evaluating the absorption of lipophilic drugs. The presence of a thick mucus barrier significantly reduces the apparent permeability coefficients (Papp) of lipophilic compounds such as testosterone and various barbiturates when compared to mucus-free Caco-2 cells. For example, testosterone showed a 43% reduction in Papp in HT-29-MTX-E12, highlighting the impact of mucus on drug diffusion. Despite having a leakier epithelial barrier than Caco-2 cells, HT-29-MTX-E12 maintains physiological relevance through its mucus-producing capacity, making it a valuable in vitro model for investigating intestinal drug absorption and the influence of mucus on permeability.